Table 1.
Baseline characteristics of the study patients.
| Baseline characteristics | N, median (%) [range] (N=16) | |
|---|---|---|
| Age (years) | 70 [20–30] | |
| Gender | Female | 11 (69) |
| Diagnosis | R/R AML | 14 (88) |
| ND secondary AML | 2 (12) | |
| BM blasts (%) | 36 [8–94] | |
| Cytogenetics | Core Binding Factor [t (8;21)] | 1 (6) |
| Diploid karyotype | 4 (25) | |
| Adverse karyotype | 6 (38) | |
| ‐ Complex | 4 (25) | |
| Miscellaneous | 5 (31) | |
| ELN 2017 risk category | Favorable risk | 1 (6) |
| Intermediate risk | 5 (31) | |
| Adverse risk | 10 (63) | |
| Mutations | ASXL1 | 4 (25) |
| DNMT3A | 3 (18) | |
| TET2 | 4 (25) | |
| RUNX1 | 5 (31) | |
| NRAS/KRAS | 7 (44) | |
| PTPN11 | 3 (18) | |
| WT1 | 2(12) | |
| Prior lines of therapy | 3 [1–6] | |
| Prior venetoclax | 13 (93) | |
| Prior allo-SCT | 6 (38) | |
N number, R/R relapsed refractory, ND newly diagnosed, ELN European LeukemiaNet, allo-SCT allogeneic stem cell transplantation.